RACHEL LACY ANDERSON
- Type
- Physician · Allopathic & Osteopathic Physicians / Family Medicine
- Where
- MOORE, OK
- NPI
- 1366584252
- Received
- $17,247 in 355 records, 2019 to 2025 ($5,005 general, $12,242 research)
- As principal investigator
- $2,814,899 of research payments to others in 1,368 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 15 | $280 |
| 2024 | General payment | 27 | $478 |
| 2024 | Research payment | 2 | $10,992 |
| 2023 | General payment | 61 | $951 |
| 2023 | Research payment | 2 | $1,250 |
| 2022 | General payment | 84 | $1,129 |
| 2021 | General payment | 39 | $684 |
| 2020 | General payment | 12 | $198 |
| 2019 | General payment | 113 | $1,283 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 4 | $12,242 |
| Food and Beverage | 349 | $4,991 |
| Education | 2 | $14 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-09-17 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-08-06 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-08-06 | Otsuka America Pharmaceutical, Inc. | $16 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-07-24 | Exact Sciences Corporation | $16 | Food and Beverage | In-kind items and services | The Cologuard Plus Collection Kit Device, Oncology | 2025 | |
| 2025-07-23 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-06-18 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-04-16 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-04-15 | Dexcom, Inc. | $37 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-04-15 | Otsuka America Pharmaceutical, Inc. | $25 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-03-19 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-02-27 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-02-13 | Novo Nordisk Inc | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-03 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-01-28 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-23 | Antares Pharma, Inc. | $21 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2025 | |
| 2024-12-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2024 | |
| 2024-12-10 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-11-27 | Exact Sciences Corporation | $16 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2024 | |
| 2024-11-05 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2024 | |
| 2024-10-24 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-10-22 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2024 | |
| 2024-09-25 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2024 | |
| 2024-09-23 | Eli Lilly and Company | $8,874 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 | |
| 2024-09-23 | Eli Lilly and Company | $2,118 | Research payment | Cash or cash equivalent | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 | |
| 2024-09-18 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-09-16 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2024 | |
| 2024-09-10 | Novartis Pharmaceuticals Corporation | $28 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-08-29 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-27 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-08-23 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-08-06 | Antares Pharma, Inc. | $25 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2024 | |
| 2024-07-31 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-06-27 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-06-13 | Exact Sciences Corporation | $15 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2024 | |
| 2024-06-06 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2024 | |
| 2024-05-21 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-30 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-04-02 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-02-09 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-02-07 | Hologic Sales and Service, LLC | $22 | Food and Beverage | In-kind items and services | THINPREP 2000 PROCESSOR Device, Diagnostics | 2024 | |
| 2024-01-31 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-25 | Antares Pharma, Inc. | $25 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2024 | |
| 2024-01-18 | IDORSIA PHARMACEUTICALS US INC | $16 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, Insomnia | 2024 | |
| 2024-01-03 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2023-12-25 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-12-20 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-12-19 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-12-14 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-11-30 | Astellas Pharma US Inc | $18 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2023 | |
| 2023-11-21 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-16 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2023 | |
| 2023-11-14 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2023 | |
| 2023-11-08 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-07 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2023 | |
| 2023-10-31 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-10-30 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-10-24 | Takeda Pharmaceuticals U.S.A., Inc. | $28 | Food and Beverage | In-kind items and services | TRINTELLIX Drug, NEUROSCIENCE | 2023 | |
| 2023-10-23 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-10-18 | IDORSIA PHARMACEUTICALS US INC | $18 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-10-11 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-10-10 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-09-27 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-09-11 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-08-22 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-08-18 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-08-16 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-08-14 | Eli Lilly and Company | $600 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH | 2023 | |
| 2023-08-02 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-07-31 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-07-27 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | 2023 | |
| 2023-07-19 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-07-18 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2023 | |
| 2023-07-13 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-06-29 | Halozyme Inc | $22 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2023 | |
| 2023-06-29 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-06-28 | Otsuka America Pharmaceutical, Inc. | $24 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-06-27 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-06-21 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2023 | |
| 2023-06-15 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | COMIRNATY Biological, VACCINES | 2023 | |
| 2023-06-14 | Novo Nordisk Inc | $25 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2023 | |
| 2023-06-08 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-06-06 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-05-25 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2023 | |
| 2023-05-18 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2023 | |
| 2023-05-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-05-11 | Otsuka America Pharmaceutical, Inc. | $24 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-05-10 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-04-18 | Supernus Pharmaceuticals, Inc. | $21 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2023 | |
| 2023-04-12 | Otsuka America Pharmaceutical, Inc. | $15 | Food and Beverage | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2023 | |
| 2023-04-10 | Eli Lilly and Company | $650 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-03-29 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2023 | |
| 2023-03-23 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | COMIRNATY Biological, VACCINES | 2023 | |
| 2023-03-23 | PFIZER INC. | $0 | Food and Beverage | In-kind items and services | COMIRNATY Biological, VACCINES | 2023 | |
| 2023-03-08 | Antares Pharma, Inc. | $17 | Food and Beverage | In-kind items and services | NOCDURNA Drug, NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | 2023 | |
| 2023-03-07 | Merck Sharp & Dohme LLC | $7 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2023 | |
| 2023-03-02 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-02-21 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-02-09 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-02-08 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2023 | |
| 2023-02-07 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-02-01 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-01-26 | Otsuka America Pharmaceutical, Inc. | $17 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-01-26 | Merck Sharp & Dohme LLC | $8 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2023 | |
| 2023-01-24 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-01-24 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-01-11 | Exact Sciences Corporation | $13 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2023 | |
| 2023-01-10 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2023 | |
| 2022-12-22 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-12-20 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-12-20 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $4 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-12-13 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2022 | |
| 2022-12-08 | Otsuka America Pharmaceutical, Inc. | $18 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2022 | |
| 2022-11-29 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $11 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-11-28 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-11-16 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2022 | |
| 2022-11-08 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-11-03 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2022 | |
| 2022-11-02 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-10-27 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-10-26 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $18 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-10-20 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-10-18 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2022 | |
| 2022-10-12 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2022 | |
| 2022-09-29 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-09-27 | Amgen Inc. | $4 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2022 | |
| 2022-09-21 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-09-14 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-09-08 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2022 | |
| 2022-09-07 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-09-07 | Amgen Inc. | $5 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2022 | |
| 2022-09-06 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2022 | |
| 2022-08-24 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2022 | |
| 2022-08-18 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-08-05 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-08-04 | Lilly USA, LLC | $4 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2022 | |
| 2022-08-02 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2022 | |
| 2022-07-27 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2022 | |
| 2022-07-27 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2022 | |
| 2022-07-26 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $19 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-07-14 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2022 | |
| 2022-06-30 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-06-21 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-06-15 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-06-14 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2022 | |
| 2022-06-08 | Esperion Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2022 | |
| 2022-06-07 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-06-02 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2022 | |
| 2022-06-01 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-05-26 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2022 | |
| 2022-05-25 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2022 | |
| 2022-05-25 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-05-18 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-05-12 | Amarin Pharma, Inc. | $19 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2022 | |
| 2022-05-12 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-05-12 | Amgen Inc. | $5 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2022 | |
| 2022-05-11 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-05-11 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2022 | |
| 2022-05-05 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-05-04 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-04-28 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2022 | |
| 2022-04-27 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-04-21 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2022 | |
| 2022-04-20 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2022 | |
| 2022-04-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-04-19 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-04-13 | Currax Pharmaceuticals LLC | $14 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2022 | |
| 2022-04-12 | Kowa Pharmaceuticals America, Inc. | $16 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2022 | |
| 2022-04-07 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-03-31 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2022 | |
| 2022-03-30 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-03-30 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-03-22 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-03-22 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-03-17 | Currax Pharmaceuticals LLC | $13 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2022 | |
| 2022-03-16 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-03-15 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2022 | |
| 2022-03-15 | Amgen Inc. | $4 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2022 | |
| 2022-03-10 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-03-10 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-03-09 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2022 | |
| 2022-02-28 | Amgen Inc. | $6 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2022 | |
| 2022-02-22 | Astellas Pharma US Inc | $15 | Food and Beverage | In-kind items and services | Myrbetriq Drug, Urology | 2022 | |
| 2022-02-16 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-02-08 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2022 | |
| 2022-02-02 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2022 | |
| 2022-01-27 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2022 | |
| 2022-01-26 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-01-19 | Lilly USA, LLC | $9 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2022 | |
| 2022-01-19 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-01-13 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $15 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-01-11 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2022 | |
| 2021-12-16 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2021 | |
| 2021-12-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-12-09 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-12-01 | Currax Pharmaceuticals LLC | $11 | Food and Beverage | In-kind items and services | CONTRAVE Drug, OBESITY | 2021 | |
| 2021-11-30 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2021-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-11-17 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-11-16 | Takeda Pharmaceuticals U.S.A., Inc. | $22 | Food and Beverage | In-kind items and services | TRINTELLIX Drug, NEUROSCIENCE | 2021 | |
| 2021-11-10 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2021 |
The latest 200 records of 355.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-19 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $243 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-12-19 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $29 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-12-19 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $2,254 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-12-19 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $1,606 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-12-19 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $1,658 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-12-19 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $484 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-12-19 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $98 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-12-15 | PFIZER INC. | TEKTON RESEARCH LLC | $702 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 |
| 2025-11-27 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $29 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-11-27 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $386 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-11-27 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $1,658 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-11-27 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $54 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-11-27 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $2,254 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-11-27 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $484 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-11-27 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $81 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-11-24 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $205 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-11-24 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $60 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-11-24 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $80 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-11-24 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $4,507 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-11-24 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $77 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | Tekton Research, LLC - Moore - PPDS | $3,100 | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran | 2025 |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | Tekton Research, LLC - Moore - PPDS | $14,000 | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran | 2025 |
| 2025-10-27 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $968 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-10-27 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $14 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-10-22 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $2,000 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-10-22 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $54 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-10-22 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $8,500 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-10-03 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $8,974 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-09-29 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $1,606 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-09-23 | ModernaTX, Inc. | TEKTON RESEARCH - MOORE OK | $33 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-09-22 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $243 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-09-22 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $108 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-08-28 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $3,316 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-08-28 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $3,213 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-08-28 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $416 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-08-28 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $4,508 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-08-07 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $913 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2025 |
| 2025-06-18 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $416 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-06-18 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $4,263 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-06-18 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $3,316 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-06-18 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $5,680 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-06-11 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $5,750 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-05-28 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $932 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-05-27 | Eli Lilly and Company | TEKTON RESEARCH INC | $368,432 | A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF W | 2025 |
| 2025-05-16 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $1,000 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-05-16 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $1,500 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-05-16 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $1,000 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-05-16 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $2,577 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-05-16 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $9,986 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-05-16 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $932 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-05-09 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $4,660 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-04-16 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $50 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-03-25 | ModernaTX, Inc. | TEKTON RESEARCH - MOORE OK | $25 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-03-24 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $7,526 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | 2025 |
| 2025-02-13 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $38 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2025 |
| 2025-02-13 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $995 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2025 |
| 2025-01-31 | Eli Lilly and Company | TEKTON RESEARCH INC | $1,118 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2025-01-31 | Eli Lilly and Company | TEKTON RESEARCH INC | $90 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-29 | ModernaTX, Inc. | TEKTON RESEARCH LLC | $1,300 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-01-07 | Eli Lilly and Company | TEKTON RESEARCH INC | $39,550 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2024-12-10 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $1,268 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-11-28 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $96 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-11-27 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $93 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-11-22 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $2,138 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-11-15 | AstraZeneca Pharmaceuticals LP | TEKTON RESEARCH INC | $13,134 | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and s | 2024 |
| 2024-10-15 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $2,304 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-10-09 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $4,000 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-10-09 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $428 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-10-08 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $531 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-10-07 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $3,055 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-09-27 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $55 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-09-25 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $5,601 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-09-18 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $6,568 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-09-13 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $165 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-09-10 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $531 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-09-03 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $402 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-08-30 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $15,525 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-08-13 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $145 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-08-13 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $38 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-08-13 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $402 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-08-07 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $402 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-08-01 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $16,057 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-07-29 | Bausch Health US, LLC | TEKTON RESEARCH LLC | $3,500 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-07-19 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $500 | A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRN | 2024 |
| 2024-07-10 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $2,706 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-07-04 | PFIZER INC. | TEKTON RESEARCH INC | $53,172 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 |
| 2024-07-03 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $3,100 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-06-27 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $84,035 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-06-25 | Astellas Pharma Global Development | TEKTON RESEARCH INC | $2,304 | A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Indi | 2024 |
| 2024-06-18 | PFIZER INC. | TEKTON RESEARCH INC | $32,481 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 |
| 2024-06-10 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $36,850 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-06-05 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $1,670 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-05-31 | PFIZER INC. | TEKTON RESEARCH INC | $87,592 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 |
| 2024-05-31 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $100 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-05-29 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $49,700 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-05-27 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $220 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-05-24 | PFIZER INC. | TEKTON RESEARCH INC | $14,055 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 |
| 2024-05-09 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $3,493 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-05-02 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $11,896 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-03-28 | ModernaTX, Inc. | Tekton Research - Beaumont - PPDS | $11,286 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Moore, OK, county Cleveland County, OK, state Oklahoma; placed by its city name.
| Measure | Place (city or town) Moore, OK | County Cleveland County, OK | State Oklahoma |
|---|---|---|---|
| Population B01003 | 63,420 | 300,047 | 4,028,634 |
| Population, 2020 census P1 | 62,793 | 295,528 | 3,959,353 |
| Median age B01002 | 34.1 | 35.4 | 37.0 |
| Under 18 B01001 | 25.7% | 20.4% | 24.0% |
| 65 and over B01001 | 13.3% | 14.9% | 16.3% |
| Households B11001 | 23,671 | 116,799 | 1,562,389 |
| Foreign born B05002 | 5.2% | 6.6% | 6.4% |
| Median household income B19013 | $80,420 | $77,068 | $65,039 |
| Median family income B19113 | $95,076 | $98,966 | $82,385 |
| Per capita income B19301 | $37,779 | $39,391 | $35,624 |
| Poverty rate B17001 | 11.4% | 12.9% | 15.3% |
| Unemployment rate B23025 | 4.7% | 4.8% | 5.0% |
| Civilian labor force B23025 | 32,927 | 157,031 | 1,921,413 |
| Mean commute (minutes) B08013 | 22.9 | 23.7 | 22.4 |
| Bachelor's degree or higher B15003 | 29.1% | 36.2% | 28.3% |
| Housing units B25001 | 24,995 | 124,442 | 1,775,127 |
| Owner-occupied B25003 | 67.9% | 63.9% | 65.8% |
| Renters B25003 | 32.1% | 36.1% | 34.2% |
| Median home value B25077 | $204,500 | $235,700 | $199,800 |
| Median gross rent B25064 | $1,340 | $1,167 | $1,014 |
| White, not Hispanic B03002 | 66.4% | 67.2% | 62.1% |
| Black B03002 | 5.5% | 4.6% | 6.8% |
| Hispanic or Latino B03002 | 13.1% | 11.0% | 12.7% |
| Asian B03002 | 3.2% | 4.7% | 2.4% |
| American Indian and Alaska Native B03002 | 2.7% | 3.4% | 6.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Moore, OK.
Comments